Comparative evaluation of effectiveness of twenty versus fifty percent autologous serum eye drops in treatment of dry eye.
Autologous serum
Sjogren syndrome
dry eye
Journal
Indian journal of ophthalmology
ISSN: 1998-3689
Titre abrégé: Indian J Ophthalmol
Pays: India
ID NLM: 0405376
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
medline:
10
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
ppublish
Résumé
The objective of the study was to compare the efficacy and safety of two concentration of autologous serum (AS) 20% vs 50% in recalcitrant moderate-to-severe dry eye patients. A double-blind prospective, interventional, and randomized study was done on 44 patients (80 eyes) clinically diagnosed with moderate-to-severe dry eye disease (DED) that was refractory to conventional treatment, and all patients were treated with AS20% or AS50% for 12 weeks. We documented Ocular Surface Disease Index (OSDI), tear film breakup time (TBUT), OXFORD corneal staining score (OSS), and Schirmer test (ST) at baseline, 2,4,8, and 12 weeks. These parameters were compared in both groups and between the groups by using Student's t-test. The study included 11 males and 33 females. Out of 80 eyes, 33 eyes had moderate and 47 had severe DED. The age of patients in AS20% was 44.73 ± 14.37 years, and in AS50% was 46.41 ± 14.47 years. The most common etiology associated with DED was secondary Sjogren syndrome. In moderate DED, both the groups showed significant improvement in both subjective and objective parameters. But in severe DED, the AS20% group failed to show any significant improvement objectively, though subjective improvement was present. In refractory severe DED patients, AS50% is better option for treatment and in moderate DED both concentrations of autologous serum are effective.
Identifiants
pubmed: 37026309
pii: IndianJOphthalmol_2023_71_4_1603_373464
doi: 10.4103/IJO.IJO_2684_22
pmc: PMC10276660
doi:
Substances chimiques
Ophthalmic Solutions
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1603-1607Déclaration de conflit d'intérêts
None
Références
Br J Ophthalmol. 1999 Apr;83(4):390-5
pubmed: 10434857
Ocul Surf. 2017 Jul;15(3):334-365
pubmed: 28736337
Cornea. 2014 Jul;33(7):663-7
pubmed: 24886995
J Clin Diagn Res. 2013 Oct;7(10):2207-10
pubmed: 24298477
Curr Eye Res. 2014 Jan;39(1):21-30
pubmed: 24074049
Ocul Surf. 2007 Apr;5(2):93-107
pubmed: 17508117
Arch Ophthalmol. 1975 Oct;93(10):1039-43
pubmed: 1180750
Indian J Ophthalmol. 2018 Feb;66(2):207-211
pubmed: 29380759
Arthritis Rheum. 1984 Apr;27(4):459-61
pubmed: 6712760
Curr Eye Res. 2013 Jan;38(1):9-17
pubmed: 22928476
Am J Ophthalmol. 2007 Jul;144(1):86-92
pubmed: 17493572
Cornea. 2001 Nov;20(8):802-6
pubmed: 11685055
Br J Ophthalmol. 2001 Oct;85(10):1188-97
pubmed: 11567963
Curr Eye Res. 2012 Aug;37(8):684-8
pubmed: 22670856
Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):619-26
pubmed: 24566903
Br J Ophthalmol. 2004 May;88(5):647-52
pubmed: 15090417
Ocul Surf. 2017 Jul;15(3):539-574
pubmed: 28736342
Biomed Res Int. 2014;2014:826970
pubmed: 25136628
Cornea. 2003 Oct;22(7):640-50
pubmed: 14508260
Am J Ophthalmol. 2005 Feb;139(2):242-6
pubmed: 15733983
Cornea. 2015 Sep;34(9):1072-8
pubmed: 26147835
Acta Ophthalmol. 2022 Mar;100(2):e396-e408
pubmed: 34137177